Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00692445 · ClinicalTrials.gov registry record · Phase 2
TC-5214 as add-on the Treatment of Major Depressive Disorder
A Phase 2 study of Depression and Major Depressive Disorder, sponsored by Targacept.
- Completed
- Registry status
- Phase 2
- Development phase
- 574
- Enrollment target
- 20
- Study locations
NCT00692445: Completed Phase 2 study of Depression and Major Depressive Disorder, sponsored by Targacept.
NCT00692445 is a Phase 2 study of Depression and Major Depressive Disorder that has completed, run by Targacept. The registered enrollment target is 574 participants, below the 785-participant average among 679 other Depression trials with a reported enrollment target (27% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00692445, a Phase 2 study of Depression and Major Depressive Disorder, has completed, sponsored by Targacept.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 574 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-center, double blind, randomized, placebo-controlled, parallel group, flexible dose titration study conducted in centers in the USA and India. Following a washout period, subject will be treated with citalopram 20 mg once daily for 4 weeks, then with 40 mg once daily for 4 weeks. Subjects who tolerate 40 mg citalopram, but whose MADRS score is \< 50% from baseline, but no lower than 17, will be considered partial or non-responders and will be randomized to receive either placebo or TC-5214 as add-on therapy. TC-5214 or placebo will be started at 2 mg daily (BID dosing), and be titrated based on tolerability and therapeutic response up to 8 mg daily. Approximately 560 subjects will enter the Open Label Phase and approximately 220 will enter the double blind phase of the study.
Conditions Studied
Interventions
- DRUG TC-5214 + citalopram
- DRUG Placebo + citalopram
Study Locations (20)
Andhra Pradesh
- Sravani Poly Clinic and Mental Health - Guntur
- Asha Hospital - Hyderabaad
- Brain Mind Behaviour Neuroscience Research Institute - Maharanipet
- VIMHANS - Vijaywada
- Government Hospital for Mental Care, Dept. of Psychiatry - Visakhapatnam
Karnataka
- Victoria Hospital, Dept. of Psychiatry - Bangalore
- St. John's Hospital - Bangalore
- Adhit Kiran Neuro Psychiatric Centre - Mangalore
- JSS Medical College Hospital, Dept. of Psychiatry - Mysore
Maharashtra
- Holy Family Hospital - Mumbai
- Deenanath Maneshkas Hospital - Pune
- Sanjeevan Hospital - Pune
- Poona Hospital & Research Centre - Pune
Florida
- Aurora Clinical Trials - Miami
Ohio
- Community Research - Cincinnati
Texas
- UT Southwestern Medical Center - Dallas
Chittoor District, Andhra Pradesh
- SV Medical College - Tirupati
Dehli
- AIIMS - New Dehli
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 574 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
What the finished NCT00692445 record still lists
NCT00692445 is an interventional study that assigns participants to a tested intervention. The registered 574 participants enrollment target is mid-sized for trials with a published cap, below the 785-participant average among 679 other Depression trials with a reported enrollment target (27% lower).
The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which TC-5214 + citalopram is the first listed.
NCT00692445 names 20 study sites across 10 states, led by Andhra Pradesh, Karnataka, Maharashtra.
Frequently Asked Questions
What is clinical trial NCT00692445 about?
NCT00692445 is a clinical study titled "TC-5214 as add-on the Treatment of Major Depressive Disorder". This is a multi-center, double blind, randomized, placebo-controlled, parallel group, flexible dose titration study conducted in centers in the USA and India. Following a washout period, subject will be treated with citalopram 20 mg once daily for 4 weeks, then with 40 mg once daily for 4 weeks. Sub...
What is the current status of trial NCT00692445?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 574 participants. The study started on 2008-06. Estimated completion is 2009-07.
What conditions does trial NCT00692445 study?
This clinical trial studies the following conditions: Depression, Major Depressive Disorder.
What interventions are being tested in trial NCT00692445?
The interventions under investigation include: TC-5214 + citalopram (DRUG), Placebo + citalopram (DRUG).
Who is sponsoring clinical trial NCT00692445?
This trial is sponsored by Targacept, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00692445 being conducted?
This trial has 20 study locations across Florida, Ohio, Texas, Andhra Pradesh, Chittoor District, Andhra Pradesh. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00692445's enrollment target sits among peer trials
574 71st of 679 higher than 609 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression
RECRUITING · Phase 2
-
Neurobiology of Suicide
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07349537 · 574 participants · Phase 1
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- NCT02610439 · 575 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer
- NCT05919264 · 575 participants · Phase 1
FOG-001 in Locally Advanced or Metastatic Solid Tumors
- NCT06583148 · 575 participants · NA
A Smoke-Free Home Intervention in Tribal Communities
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia